Figure 8. Immunization with DCs pulsed with MOG₁₉₆ activates Qa-1^b/MOG₁₉₆ tetramer⁺ cells that specifically accumulate in cervical lymph nodes.

(A) C57BL/6 mice (5 mice/group) were immunized with MOG_35-55 for EAE. Ten days later, when paralytic symptoms began, animals received one intravenous immunization with mytomycin C-treated DC2.4 or MOG₁₉₆-pulsed DC2.4 (DC2.4/MOG₁₉₆). Four days later, mononuclear cells prepared from spleens and cervical lymph nodes were examined for the presence of Qa-1^b/MOG₁₉₆ and I-A^b/MOG_38-49 tetramer⁺ cells by flow cytometry. (B) Representative plots of Qa-1^b/MOG₁₉₆ tetramer⁺ cells among CD8⁺ T cells in cervical lymph nodes and spleens. (C) Cumulative data of Qa-1^b/MOG₁₉₆ tetramer⁺ cells from five mice. *P < 0.05. Two-way ANOVA test. (D) Representative plots of I-A^b/MOG_38-49 tetramer⁺ cells among CD8⁻ T cells in cervical lymph nodes and spleens. (E) Cumulative data of I-A^b/MOG_38-49 tetramer⁺ cells from five mice. *P < 0.05. Two-way ANOVA test. (F) Experimental design for “G”: C57BL/6 mice were intravenously immunized with MOG₁₉₆-pulsed DC2.4 cells at days 0 and 10. Ten days after the last immunization, mononuclear cells from cervical lymph nodes and spleens were examined for the expressions of CD122 and Ly49 on Qa-1^b/MOG₁₉₆ tetramer⁺ CD8⁺ T cells by flow cytometry. (G) Representative FACS plots from two independent experiments were shown.